PDL BioPharma Inc. (PDLI)

[Trinityz1]

Saw that today
Looked like good news to me and then watched after market trades go whackadoo

[Penny Roger$]

News out

PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015
Contributors: PDL BioPharma, Inc
Monday, May 09, 2011 3:08 PM



INCLINE VILLAGE, Nev., May 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced that it intends to offer, subject to market and other conditions, $135 million aggregate principal amount of new convertible senior notes due May 2015 under the Company's shelf re
Tags: Stock Offering
http://www.prnewswire.com/news-releases/pdl-biopharma-inc-announces-proposed-135-million-public-offering-of-new-convertible-senior-notes-due-2015-121523349.html

[Trinityz1]

PDL BioPharma to Present at Upcoming Conferences

PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the following upcoming conferences:
Tenth Annual JMP Securities Research Conference

Tuesday, May 10, 2011

2:00 p.m. PDT

San Francisco, CA


Bank of America Merrill Lynch 2011 Health Care Conference

Wednesday, May 11, 2011

1:00 p.m. PDT

Las Vegas, NV



These presentations will be available to interested parties through live and archived audio webcasts. To access the live and subsequently archived webcasts of the presentation, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the events to allow for any software download that may be necessary. The archived webcasts will be available for seven days following each presentation.

http://ih.advfn.com/p.php?pid=nmona&article=47503185&symbol=PDLI

[Trinityz1]

think they got those notes taken care of until 2014

imo, it should be ripe for a takeover at $10 - $12

profits are up

PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the first quarter ended March 31, 2011.

Total revenues for the first quarter of 2011 were $83.3 million, compared to $62.1 million for the same period of 2010, and include a one-time settlement payment of $10 million from UCB Pharma resolving all legal disputes between the two companies. Excluding the one-time settlement payment, total revenue increased 18 percent for the first quarter of 2011 when compared to total revenue for the same period of 2010.

[Ecomike]

Any thoughts on the quarterly report data, and future here?

PE is low, Dividend is great, legal issues seem to be over or nearly over, but still has convertible notes (debt due in 2012?) and negative stock holders equity?

[Trinityz1]

PDL BioPharma to Announce First Quarter 2011 Financial Results on April 27, 2011

http://ih.advfn.com/p.php?pid=nmona&article=47367617&symbol=PDLI

[Trinityz1]

PDL BioPharma to Hold Annual Meeting of Stockholders on June 22, 2011

http://ih.advfn.com/p.php?pid=nmona&article=47332051&symbol=PDLI

[Trinityz1]

unreal
PDLI has broken $6 again.
It just keeps going and going.
Looks like I need to find something else to short.

[Ecomike]

I am on the sideline, but it recently won some court cases (or out of court settlements) IIRC, and announced a nice REAL FAT quarterly regular dividend, IIRC.

[Trinityz1]

what in the world is going on here with PDLI!?!?!?

it's taking off all of a sudden........

wonder what's going on........

[HowHi]

Agree with you,it make sense for Roche,or others to buy them out,since they are using their patents. Plus pdli have good earnings, Offer $10 a share,which is 1.7 bil, you can make it back in like 5 years(assuming sales remain the same), plus pdli have cash. GLTA

[HowHi]

What will happen to their Queen patent when it expires (2014), where will they get rev? Man this stock is a great day trader stock low and high 2% different. I been noticing for the last 2 weeks that the stock will close even or a little higher,so i buy @ 5.4 range and sell @ 5.5 range.GLTA

[Trinityz1]

PDLI just got upgraded to a hold
interesting in my email

PDLI New
Rating HOLD
Upgrade

Ratings Change for PDL Biopharma Inc (PDLI):
Upgraded to HOLD from REDUCE on 3/21/11

P/E Ratio 10.85x

% Held by Inst 80.31%

Annual Dividend/Yield $0.60/10.83%

Short Interest (% of float as of 02/28/11) 8.27%

Market Cap ($) 773.8M

Shares Out. 139.7M

have to wonder what the heck could happen here if there's a
short squeeze

[Trinityz1]

other companies want this company
they just been trying to get by hook or crook
shorting down the sp
and those bs court cases after PDLI won hands down in the patent court

this would be at $12 easy if that hadn't happened
but then
I wouldn't have done as well on puts

I just don't like seeing any company get screwed over
this is like making money with a scamming pink dang near

[HowHi]

Yep,10% dividend that's unheard of. I been trying for 1-2% gain. If I can't make 1-2%,I'll hold to get 2.5% dividend next qrt. IMO,high dividend can mean 2 things, 1. company got no other investment to invest to make $, 2. company got too much cash. I am surprise there's no big company looking to buy this. They have 3 drug in phase three with big companies. I don't know if those phase 3 have a good chance of approval or not. IMO,GLTA

[Trinityz1]

Basically once PDLI won in the Patent court hands down only to have a jury trial screw them over
and hand their royalties back to Big Pharma
as far as I'm concerned, anything goes here

read some prior posts
My opinion is that a big Pharma wants to snag PDLI and take them over for pennies on the dollar

the company is paying better than a 10% dividend
it should be trading at $12
and if shorts start to cover......good grief it could happen.

so they're getting screwed over....
every time the sp makes any progress, it gets shorted back down
so imo, there isn't that much to like right now except the qualified dividend which pays a nice chunk of change

right now a 5% dividend is outstanding from any company
the avg is running less than 3%
So until it gets a fair shake, I short on the highs as fast as I can then cover on the drops

Imo, there's nothing wrong with the company and I made some nice $ on previous dividends

I probably will throw up if it shoots up to $12 in a short period of time and will wish I had loaded the boat with shares and calls

[Trinityz1]

you know as much as I do

[HowHi]

I like this stock even better since most lawsuit are cleared. So it looks like PDLI will get less royalties from now on(right). Is the Roche lawsuit in PDLI favor for Roche. What are the chance of their pipeline getting approve. I no new pipeline,how long can these royalties hold up. GLTA

[Trinityz1]

someone is working overtime to push the sp down
someone has a MM or two in their pocket

still say a big pharma is trying hard to snag this company for cheap

might be time for some puts again

[Trinityz1]

well, looks like PDLI has finally settled down
Look for the shorts to clear out and go look for greener pastures
Here's a 10%+ dividend payer

[Trinityz1]

up over 20% in the past week
Whew! glad my puts are done!

well over the next year or so (12-15 months) I expect this one to be around $10-$12

might be a good long term and some calls might be in order

[Trinityz1]

PDL Revs Up, Settles Disputes - Analyst Blog
9:15a ET March 1, 2011 (Zacks.com)

PDL BioPharma Inc. (PDLI) posted fourth quarter earnings of 20 cents per share, above the year-ago figure of 17 cents. Higher revenues boosted earnings in the quarter. Earnings per share were, however, a penny short of the Zacks Consensus Estimate of 21 cents.

For full year 2010, PDL reported earnings per share of 97 cents, down from $1.06 per share in 2009 but ahead of the Zacks Consensus Estimate of 90 cents. Full year 2010 revenues of $345 million were well above the prior-year figure of $318.2 million. Revenues also beat the Zacks Consensus Estimate of $343 million. 2009 revenues included royalties from MedImmune, a subsidiary of AstraZeneca (AZN), on sales of Synagis, which PDL no longer receives. Excluding this revenue, sales were up 30% over the prior year.

Quarterly Details

Fourth quarter revenue of $76.1 million was higher than the Zacks Consensus Estimate of $74 million and the year-ago revenue of $58.3 million. The top-line increase resulted from higher sales of Roche’s (RHHBY) Avastin, Herceptin, Lucentis and Biogen (BIIB)/Elan’s (ELN) Tysabri, in the third quarter of 2010, on which PDL BioPharma received royalties in the fourth quarter. Revenue in the reported quarter also outdid the company guidance of $74 million provided in December 2010.

General and administrative expenses increased from $5.5 million in the year-earlier quarter to $12.1 million in the fourth quarter of 2010. Increased legal costs perpetrated the rise in expenses.

PDL announced that it is shifting from a special dividend policy to a regular dividend policy of paying dividend of 15 cents in each quarter.

On the legal front, PDL resolved patent disputes with Novartis (NVS), MedImmune, and UCB Pharma S.A. (UCBJF) in the quarter.

Settlement with MedImmune

In February 2011, PDL resolved all legal disputes with MedImmune, a subsidiary of AstraZeneca, for $92.5 million including payments related to royalties on sales of MedImmune’s product Synagis (a respiratory virus treatment) and PDL’s patents. This dispute has been ongoing since December 2008.

Under the definitive settlement agreement, PDL paid MedImmune $65 million and will pay another $27.5 million by February 10, 2012. MedImmune has not paid any royalties to PDL since September 2009 on Synagis sales and is not liable to pay any further royalties to PDL, either on past or future sales. MedImmune will not challenge the Queen et al. patents henceforth or assist any other parties involved in opposing the European patent ‘216B (key Queen patent in EU).

Settlement with UCB Pharma

In February 2011, PDL entered into a settlement with UCB Pharma to refrain from suing the latter for any royalties on UCB’s drug Cimzia under the Queen et al. patents. This settlement marks the end of all legal disputes between the two companies. In the process, PDLI received a lump sum payment of $10 million from UCB. UCB consequently withdrew its challenge to the European patent ‘216B in the European Patent Office (EPO).

Settlement with Novartis

In late February 2011, PDL entered into a settlement agreement with Novartis under which PDL agreed to dismiss all claims against Novartis as well as the Nevada lawsuit. Novartis also withdrew its opposition appeal to the European patent ‘216B. PDL will get lower royalties on net sales of Lucentis under the settlement agreement. The litigation with Roche, however, continues.

In February 2011, the acquisition of BioTransplant (a bankrupt company) by PDL was approved and BioTransplant subsequently withdrew its opposition appeal challenging the validity of the ‘216B patent. Following the settlements with MedImmune, UCB Pharma and Novartis, and the acquisition of BioTransplant, all the parties challenging the validity of the ‘216 B patents have formally withdrawn their participation. Accordingly, the EPO validated its 2007 decision upholding the ’216B patent.

We believe that the validation of the European patent means limited risk to ex-US royalties. In 2010, PDL generated 35% of revenues from sales of products manufactured and sold outside the US. The validation of the ‘216B patent minimizes the risk to this source of ex-US revenue.

[R U kidding me]

Please let me try to clear up some confusion
in my post in ref. to the dates I posted as I
understand it to be.

If your in by the 3rd,plus three day settlement, =
showing ownership by the 8th.Pay day (Div.) is on the 15th

I hope this clears up any confusion

this is all my humble opinion

[mlkrborn]

Shares of PDL BioPharma (PDLI 5.60, +0.05, +0.90%) rallied 16% on news the biotech group plans to pay a quarterly dividend of 15 cents per share, beginning on March 15.

PDL also announced that it has resolved its dispute with Novartis AG (NVS 56.18, -0.09, -0.16%) over PDL’s “Queen” patent. Under the agreement, Novartis has agreed not to challenge the validity of the Queen patent to European authorities. In exchange, PDL will make certain payments to Novartis on sales of the eye care drug Lucentis.



Lucentis, which utilizes PDL technology, is marketed by Roche’s (RHHBY 37.56, +0.51, +1.38%) Genentech unit in the U.S. and Novartis overseas.

PDL added that the agreement with Novartis does not affect its ongoing litigation against Roche’s Genentech filed in a Nevada state court.

[Trinityz1]

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60401419

[R U kidding me]

PDL BioPharma, Inc. (PDL) (Nasdaq:PDLI - News) today announced that its board of directors has adopted a regular dividend policy for 2011 and beyond and declared that the four quarterly dividends to be paid to its stockholders in 2011 will be $0.15 per share of common stock. The $0.15 dividends will be paid on March 15, June 15, September 15 and December 15 to all stockholders who own shares of PDL on March 8, June 8, September 8, and December 8, the Record Dates for each of the dividend payments, respectively

March 8th, Sorry,I stated the 3rd on my last post

[Trinityz1]

PDL BIOPHARMA INC (NASDAQ:PDLI)

PDL BioPharma Inc., formerly Protein Design Labs, Inc., is a biopharmaceutical company focused on discovering, developing and commercializing therapies for severe or life threatening illnesses. The Company markets and sells products in the acute care hospital setting in the United States and Canada, and receives royalties through licensing agreements with a number of biotechnology and pharmaceutical companies based on its antibody humanization technology platform. The Company's product development pipeline includes six investigational compounds in Phase II or Phase III clinical development for hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer. On March 23, 2005, the Company completed the acquisition of all of the outstanding stock of ESP Pharma Holding Company, Inc. (ESP Pharma), a privately held hospital-focused company. It also acquired from Centocor, Inc. (Centocor) the right to manufacture, develop, market and distribute Retavase in the United States and Canada during the year ended December 31, 2005. Marketed Products The Company's portfolio of actively marketed products consists of three biopharmaceutical products. Cardene IV is a branded, United States-approved dihydropyridine class calcium channel blocker delivered intravenously that is indicated for short-term treatment of hypertension when oral therapy is not feasible or desirable. Retavase is indicated for use in the management of heart attacks (acute myocardial infarction (AMI)) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI. The Company re-launched Retavase in April 2005, after acquiring it in March 2005. IV Busulfex, an IV formulation of busulfan, is a chemotherapeutic agent used as part of a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. IV Busulfex provides anti-tumor effect to eradicate residual malignancy, ablation of the bone marrow to make space for the new source of stem cells and to provide immunosuppression to prevent graft rejection. IV Busulfex was launched in Europe by Pierre Fabre Medicament S.A. (Pierre Fabre) and in several Asian countries by Kirin Brewery Company, Limited (Kirin). Both Pierre Fabre and Kirin are the Company's distributors in their territories. Products in Clinical Development PDL BioPharma Inc. is engaged in the discovery and development of protein-based therapeutic products, with the majority of its emphasis based upon deriving humanized antibody product candidates employing its platform. The Company has six product candidates in clinical development for various disease indications. Four of these are antibodies and are in clinical development with a near-term emphasis on autoimmune and inflammatory diseases and cancer, specifically inflammatory bowel disease, asthma, multiple sclerosis (MS) and solid tumors. The remaining two product candidates, ularitide and terlipressin, were added to the portfolio through the Company's acquisition of ESP Pharma. Terlipressin is a synthetic, 12-amino acid peptide (1-triglycyl-8-lysine-vasopressin) derived from the natural hormone lysine-vasopressin. Due to its constrictive activity on vascular and extra-vascular smooth muscle cells (V-1 agonist), it reduces blood flow in the splanchnic area, and thereby lowers portal blood pressure. Terlipressin is in Phase III clinical development for the treatment of type 1 hepatorenal syndrome. Under an agreement with Orphan Therapeutics, PDL BioPharma Inc. holds marketing, sales and distribution rights for terlipressin in the United States and Canada. Orphan Therapeutics holds the investigational new drug (IND) application for terlipressin and is conducting the Phase III clinical trial in the United States and Europe. The ongoing clinical study, conducted by Orphan Therapeutics, is a double-blind, placebo-controlled Phase III trial of terlipressin in patients with type 1 hepatorenal

http://www.buyins.net/tools/symbol_stats.php?sym=pdli

[Trinityz1]

well the volatility should finally settle down
.15 quarterly dividends means we shouldn't see much of a downward hit
when dividends are paid
it's a modest dividend and consistent and should help the sp rise

If Roche & Genentech finally have to pay up, I'd say $10-$12 is in the cards

this company has taken a horrific beating
MM's dropped it by $1.18 on negative lawsuit news at one time
I'm still of the firm belief that one of those big Pharmas was out to try and take them over

Now one of the main things is to see the short position get reduced
I bet there's some shorts out there wishing they had covered below $5

so maybe this one will finally get interesting again

[R U kidding me]

Yes: calls i got the first 50 aug.6's
out of the gate this morring. Paid a little too much (.35)
just did'nt want to miss them.Picked this stock off the pre-market most active list. Will like to see that tsunami.I think you have to be in the stock by the march 3rd ??? to recive the .15 div. for 1st q.?? Will look for a good 3 day run.
thank you for your reply and good luck to you.

[Trinityz1]

PDLI headed for trading 10 million + shares today

this one just finally might be out of the woods
guess I should've bought some calls last Friday

dang, if I had only known........sigh

[Trinityz1]

plus PDLI finally announced regular dividends of .15 every quarter
Mar 15, June 15, Sept, 15 and Dec 15

European Patent court ruled in PDLI's favor and canceled all appeals
against them

[Trinityz1]

$6 is the next ceiling to break
with the new FINRA rules taking effect today
the shorts in PDLI must be hurting or gonna be hurting

I keep seeing little stabs at stopping this tsunami that's started
and it's not working

[R U kidding me]

Broke 5.60s next stop 5.90s

[Trinityz1]

Imo, a big Pharma company wants this company
I still can't believe they got screwed over in that lawsuit
after winning in the patent court

but these days....just about any company can get screwed over

[Trinityz1]

nasty business that

[surf1944]

7:00AM PDL BioPharma and MedImmune Resolve Patent Disputes; PDL to pay MedImmune $92.5 Million (PDLI) 5.44 : Co announces that PDL and MedImmune, LLC have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to MedImmune's product Synagis and PDL's patents known as the Queen et al. patents. Under the settlement agreement, PDL paid MedImmune $65 million on February 15, 2011 and will pay $27.5 million by February 10, 2012 for a total of $92.5 million. MedImmune has not paid royalties to PDL on sales of Synagis that occurred after September 30, 2009. No further payments will be owed by MedImmune to PDL under its license to the Queen et al. patents as a result of past or future Synagis sales. As part of the settlement agreement, MedImmune has agreed not to challenge or assist other parties in challenging the Queen et al. patents.

[Trinityz1]

interesting...and all it got was a .02 pop in sp

UCB and PDL BioPharma Resolve Patent Disputes

Pdl Biopharma, Inc. (MM) (NASDAQ:PDLI)
Intraday Stock Chart

Today : Tuesday 8 February 2011


UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia (certolizumab pegol), and PDL's patents known as the Queen et al. patents.

Under the settlement agreement, PDL provided UCB a covenant not to sue UCB for any royalties regarding UCB's Cimzia product under the Queen patent portfolio in return for a lump sum payment of US$10 million and the mutual resolution of other disputes between the two companies, including two pending patent interferences before the United States Patent and Trademark Office and a patent opposition in the European Patent Office. No additional payments will be owed by UCB to PDL under the Queen patents in respect of Cimzia sales for any indication and the sale of a product in development that may or may not be approved within the term of the Queen patents.

About Cimzia

Cimzia® is a pegylated, humanized TNFa (tumor necrosis factor alpha) antibody fragment. The U.S. Food and Drug Administration has approved Cimzia for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). Cimzia in combination with methotrexate (MTX), is approved in the EU for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease modifying antirheumatic drugs including MTX. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia is a registered trademark of UCB.

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward Looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements, including because UCB or PDL fail to timely fulfill their respective obligations under the settlement agreement. PDL and UCB expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their respective expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

SOURCE PDL BioPharma, Inc.

http://ih.advfn.com/p.php?pid=nmona&article=46342276&symbol=PDLI

[Trinityz1]

speaking of toast
down -.26 today so far

getting ripped apart

[Trinityz1]

imo, one of the Big Pharma's wants PDLI's patents all to themselves without having to pay any royalties

I've been expecting a buyout offer
especially after that jury totally screwed them over

with my luck they'll get $10 a share and totally screw me on my puts

[Trinityz1]

of course....that last jury verdict against PDLI was complete and total crap, imo

they win in the patent court
and then a jury screws them over
all in favor of big pharma

and it looks like it will repeat in March

[Trinityz1]

mud....pdli is mud
toast.

not much else to say about it.

[Trinityz1]

if they settle that lawsuit bit again
would be something to see
kinda thought they might get it done by Dec and announce another special dividend

that would drive the sp up and make options look attractive to trade
they haven't even announced any dividends for next year yet

everytime it gains any ground the past year, it just gets knocked back down
or so it seems when I look at it every 3-4 weeks
looked at some options the other day, but they were over priced, imo
as they seem to have been for some time

my puts did well...can't complain there
market is so crazy these days

it's been tough for me to touch much of anything
figure wait until Jan after the repugs get in office and see if we have another giant crash and ride a shorting wave

[Pro-Life]

PDLI Today's 8K Filing:

http://phx.corporate-ir.net/phoenix.zhtml?c=100463&p=irol-SECText&TEXT=aHR0cDovL2lyLmludC53ZXN0bGF3YnVzaW5lc3MuY29tL2RvY3VtZW50L3YxLzAwMDExNDQyMDQtMTAtMDYxMjE4L3htbA%3d%3d

Royalty revenue:

http://pdl.com/royalty-revenue/

News archive:

http://phx.corporate-ir.net/phoenix.zhtml?c=100463&p=irol-news&nyo=0

Daily chart:



Weekly chart:

[Trinityz1]

PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012
Pdl Biopharma (MM) (NASDAQ:PDLI)
Intraday Stock Chart

Today : Wednesday 27 October 2010


PDL BioPharma, Inc. (PDL, the Company) (Nasdaq: PDLI) today announced that it has entered into separate privately negotiated exchange agreements under which it will retire $92.0 million in aggregate principal of the Company's outstanding 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes). Pursuant to the exchange agreements, the holders of the 2012 Notes will receive $92.0 million in aggregate principal of new 2.875% Convertible Senior Notes due February 15, 2015 (the 2015 Notes). Following the exchange, $136.0 million of the 2012 Notes will remain outstanding.

The Company also announced that it entered into privately negotiated agreements to place an additional $88.0 million in aggregate principal amount of the 2015 Notes for cash. The net cash proceeds from the issuance of such 2015 Notes will be used for corporate, capital management and business development purposes. The shares of the Company's common stock issuable upon the conversion of the 2015 Notes have been reserved for issuance by the Company and listed on the NASDAQ Stock Market.

The issuance of the 2015 Notes will not be registered under the Securities Act of 1933, as amended, in reliance on exemption from registration thereunder.

No Solicitation

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering would be unlawful.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-Looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:
The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
The outcome of pending litigation or disputes; and
The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" section of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

SOURCE PDL BioPharma, Inc.

http://ih.advfn.com/p.php?pid=nmona&article=44954461&symbol=PDLI

[Trinityz1]

are they going to present how they've screwed the pooch with mismanagement and how this resulted in the sp taking a nosedive?

[califax]

Chart ( daily / weekly )

[califax]

PDL BioPharma to Present at Upcoming Investor Conferences

Date : 09/15/2010 @ 7:00AM
Source : PR Newswire
Stock : Pdl Biopharma (MM) (PDLI)

http://ih.advfn.com/p.php?pid=nmona&article=44375940&symbol=PDLI

PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences.

UBS Global Life Sciences Conference

Tuesday, September 21, 2010

2:30 p.m. ET

New York City

5th Annual JMP Securities Healthcare Conference

Monday, September 27, 2010

9:00 a.m. ET

New York City

To access the live and subsequently archived webcasts of the presentations, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following each presentation.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.

[Trinityz1]

yep and the sp dropped like a rock to the tune of $1.18 right off the bat
saw it go across the bottom of the tv screen

that wee bit of news cost investors $1.18 a share in value in nothing flat

[califax]

Morgan Stanley Global Healthcare Unplugged Conference

Tuesday, September 14, 2010
3:55 p.m. Eastern time
New York City

http://finance.yahoo.com/news/PDL-BioPharma-to-Present-at-prnews-931969264.html?x=0&.v=1

[califax]

Presentation at the Rodman & Renshaw 12th Annual Healthcare Conference

On September 13, 2010, PDL BioPharma, Inc. (the “Company”) will make a presentation at the Rodman & Renshaw 12th Annual Healthcare Conference in New York City, New York. A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.

LINK: http://phx.corporate-ir.net/phoenix.zhtml?c=100463&p=irol-SECText&TEXT=aHR0cDovL2lyLmludC53ZXN0bGF3YnVzaW5lc3MuY29tL2RvY3VtZW50L3YxLzAwMDExNDQyMDQtMTAtMDQ5MDgyL3htbA%3d%3d

---



LINK: http://phx.corporate-ir.net/phoenix.zhtml?c=100463&p=irol-secText&TEXT=aHR0cDovL2lyLmludC53ZXN0bGF3YnVzaW5lc3MuY29tL2RvY3VtZW50L3YxLzAwMDExNDQyMDQtMTAtMDQ5MDgyL3htbC9zdWJkb2N1bWVudC8y